Science Explorer Back to mapMap
Discussion
Company · Somerset · United States

Vifor Pharma (United States)

World rank, all time
#31,992
of 34,923
Rank in United States
#6,738
of 7,310
Research works
185
▲ 74% vs 2018-21
Citations
3.7k
20.2 per fractional work
Top-10% rate
13.9%
all institutions 10.0%
vs its own fields
0.93×
1.00× is exactly expected
Open access
45%
world 40%
International
39%
world 18%

Which fields of science does Vifor Pharma (United States) work in?

In 2022-now, 52% of research at Vifor Pharma (United States) is in Health Sciences, 25% in Life Sciences. Its largest fields are Medicine (49%), Biochemistry, Genetics and Molecular Biology (16%), Economics, Econometrics and Finance (5%). It does 2.1× the world's share of Health Sciences.

Health Sciences: 35 fractional works · 52.2% of its workMedicine: 33 fractional works · 49.3% of its workPulmonary and Respiratory Medicine: 4 fractional works · 6.4% of its workHematology: 3 fractional works · 4.6% of its workOncology: 3 fractional works · 4.5% of its workGenetics: 2 fractional works · 3.6% of its workRadiology, Nuclear Medicine and Imaging: 2 fractional works · 2.7% of its workPhysiology: 2 fractional works · 2.7% of its workNeurology: 2 fractional works · 2.4% of its workInfectious Diseases: 1 fractional works · 2.0% of its workEpidemiology: 1 fractional works · 2.0% of its workPublic Health, Environmental and Occupational Health: 1 fractional works · 2.0% of its workDermatology: 1 fractional works · 1.8% of its workPathology and Forensic Medicine: 1 fractional works · 1.8% of its workPharmacology: 1 fractional works · 1.7% of its workRheumatology: 1 fractional works · 1.7% of its workPediatrics, Perinatology and Child Health: 1 fractional works · 1.2% of its workNephrology: 1 fractional works · 1.2% of its workGastroenterology: 1 fractional works · 1.1% of its workSurgery: 1 fractional works · 0.9% of its workGeriatrics and Gerontology: 0 fractional works · 0.7% of its workCardiology and Cardiovascular Medicine: 0 fractional works · 0.6% of its workOphthalmology: 0 fractional works · 0.6% of its workReproductive Medicine: 0 fractional works · 0.5% of its workFamily Practice: 0 fractional works · 0.5% of its workEndocrinology, Diabetes and Metabolism: 0 fractional works · 0.4% of its workEmergency Medicine: 0 fractional works · 0.4% of its workPsychiatry and Mental health: 0 fractional works · 0.3% of its workComplementary and alternative medicine: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.7% of its workNursing: 1 fractional works · 2.2% of its workNutrition and Dietetics: 1 fractional works · 2.2% of its workHealth Professions: 0 fractional works · 0.6% of its workHealth Information Management: 0 fractional works · 0.3% of its workOccupational Therapy: 0 fractional works · 0.2% of its workSmaller subfields together: 0 fractional works · 0.1% of its workVeterinary: 0 fractional works · 0.1% of its workLife Sciences: 17 fractional works · 25.0% of its workBiochemistry, Genetics and Molecular Biology: 10 fractional works · 15.6% of its workMolecular Biology: 7 fractional works · 10.9% of its workGenetics: 1 fractional works · 1.9% of its workCancer Research: 1 fractional works · 0.9% of its workBiotechnology: 0 fractional works · 0.5% of its workCell Biology: 0 fractional works · 0.5% of its workBiophysics: 0 fractional works · 0.4% of its workMolecular Medicine: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.2% of its workImmunology and Microbiology: 3 fractional works · 4.4% of its workImmunology: 2 fractional works · 3.4% of its workMicrobiology: 0 fractional works · 0.5% of its workVirology: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.2% of its workAgricultural and Biological Sciences: 1 fractional works · 2.1% of its workPlant Science: 1 fractional works · 1.1% of its workFood Science: 0 fractional works · 0.8% of its workAquatic Science: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.0% of its workPharmacology, Toxicology and Pharmaceutics: 1 fractional works · 1.5% of its workPharmaceutical Science: 1 fractional works · 0.8% of its workPharmacology: 0 fractional works · 0.7% of its workNeuroscience: 1 fractional works · 1.3% of its workCellular and Molecular Neuroscience: 1 fractional works · 1.0% of its workSmaller subfields together: 0 fractional works · 0.3% of its workPhysical Sciences: 8 fractional works · 12.2% of its workChemistry: 3 fractional works · 4.0% of its workSpectroscopy: 1 fractional works · 1.4% of its workAnalytical Chemistry: 1 fractional works · 1.4% of its workOrganic Chemistry: 1 fractional works · 1.1% of its workComputer Science: 2 fractional works · 3.1% of its workComputer Networks and Communications: 1 fractional works · 1.1% of its workArtificial Intelligence: 1 fractional works · 1.1% of its workInformation Systems: 0 fractional works · 0.5% of its workComputational Theory and Mathematics: 0 fractional works · 0.4% of its workEngineering: 2 fractional works · 2.8% of its workBiomedical Engineering: 2 fractional works · 2.5% of its workSmaller subfields together: 0 fractional works · 0.4% of its workMaterials Science: 1 fractional works · 1.7% of its workBiomaterials: 1 fractional works · 1.1% of its workMaterials Chemistry: 0 fractional works · 0.4% of its workElectronic, Optical and Magnetic Materials: 0 fractional works · 0.3% of its workEnvironmental Science: 0 fractional works · 0.6% of its workHealth, Toxicology and Mutagenesis: 0 fractional works · 0.5% of its workSmaller subfields together: 0 fractional works · 0.1% of its workSocial Sciences: 7 fractional works · 10.6% of its workEconomics, Econometrics and Finance: 3 fractional works · 5.1% of its workEconomics and Econometrics: 3 fractional works · 5.1% of its workBusiness, Management and Accounting: 2 fractional works · 3.1% of its workBusiness and International Management: 1 fractional works · 1.5% of its workManagement of Technology and Innovation: 1 fractional works · 1.0% of its workOrganizational Behavior and Human Resource Management: 0 fractional works · 0.3% of its workStrategy and Management: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.1% of its workSocial Sciences: 1 fractional works · 1.9% of its workSociology and Political Science: 0 fractional works · 0.8% of its workCultural Studies: 0 fractional works · 0.3% of its workEducation: 0 fractional works · 0.3% of its workGender Studies: 0 fractional works · 0.3% of its workPolitical Science and International Relations: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.2% of its workPsychology: 0 fractional works · 0.5% of its workClinical Psychology: 0 fractional works · 0.3% of its workSocial Psychology: 0 fractional works · 0.3% of its workALL ITS WORKVifor Pharma(United States)67fractional works, 2022-now
Life Sciences25%Physical Sciences12%Health Sciences52%Social Sciences11%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in 2022-now. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 18 fields, with their numbers
    1. Medicine3349.3%
    2. Nursing12.2%
    3. Health Professions00.6%
    4. Veterinary00.1%
    1. Biochemistry, Genetics and Molecular Biology1015.6%
    2. Immunology and Microbiology34.4%
    3. Agricultural and Biological Sciences12.1%
    4. Pharmacology, Toxicology and Pharmaceutics11.5%
    5. Neuroscience11.3%
    1. Chemistry34.0%
    2. Computer Science23.1%
    3. Engineering22.8%
    4. Materials Science11.7%
    5. Environmental Science00.6%
    1. Economics, Econometrics and Finance35.1%
    2. Business, Management and Accounting23.1%
    3. Social Sciences11.9%
    4. Psychology00.5%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Agricultural and Biological Sciences: 0.44× its world share, 1 worksAgricultural and Bio…Biochemistry, Genetics and Molecular Biology: 2.93× its world share, 10 worksBiochemistry, Geneti…Immunology and Microbiology: 4.36× its world share, 3 worksImmunology and Micro…Neuroscience: 0.81× its world share, 1 worksNeurosciencePharmacology, Toxicology and Pharmaceutics: 4.37× its world share, 1 worksPharmacology, Toxico…Chemistry: 2.53× its world share, 3 worksChemistryComputer Science: 0.40× its world share, 2 worksComputer ScienceEngineering: 0.19× its world share, 2 worksEngineeringEnvironmental Science: 0.12× its world share, 0 worksEnvironmental ScienceMaterials Science: 0.48× its world share, 1 worksMaterials ScienceHealth Professions: 0.22× its world share, 0 worksHealth ProfessionsMedicine: 2.57× its world share, 33 worksMedicineNursing: 4.51× its world share, 2 worksNursingVeterinary: 0.74× its world share, 0 worksVeterinaryBusiness, Management and Accounting: 0.97× its world share, 2 worksBusiness, Management…Economics, Econometrics and Finance: 2.37× its world share, 3 worksEconomics, Econometr…Psychology: 0.16× its world share, 0 worksPsychologySocial Sciences: 0.15× its world share, 1 worksSocial Sciences1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Nursing, 4.5×. Every wedge is a field page.

All 18 fields, with their numbers
  1. Nursing4.51×2 works
  2. Pharmacology, Toxicology and Pharmaceutics4.37×1 works
  3. Immunology and Microbiology4.36×3 works
  4. Biochemistry, Genetics and Molecular Biology2.93×10 works
  5. Medicine2.57×33 works
  6. Chemistry2.53×3 works
  7. Economics, Econometrics and Finance2.37×3 works
  8. Business, Management and Accounting0.97×2 works
  9. Neuroscience0.81×1 works
  10. Veterinary0.74×0 works
  11. Materials Science0.48×1 works
  12. Agricultural and Biological Sciences0.44×1 works
  13. Computer Science0.40×2 works
  14. Health Professions0.22×0 works
  15. Engineering0.19×2 works
  16. Psychology0.16×0 works
  17. Social Sciences0.15×1 works
  18. Environmental Science0.12×0 works

Who are the top researchers at Vifor Pharma (United States)?

Ranked on the quality score, Alain Romero, Priyajeet S. Parekh and Susan P. Arthur lead among researchers whose main affiliation is Vifor Pharma (United States).

  1. 1 Alain Romero United States · #790,912 worldwide 2k citations · 28 works
  2. 2 Priyajeet S. Parekh United States · #2,326,220 worldwide 261 citations · 20 works
  3. 3 Susan P. Arthur United States · #3,106,432 worldwide 887 citations · 27 works
  4. 4 Christopher G. Rowan United States · #3,130,153 worldwide 936 citations · 52 works
  5. 5 Jennifer A. Kammerer United States · #3,296,956 worldwide 99 citations · 22 works
  6. 6 Peter Geisser United States · #3,498,926 worldwide 1.1k citations · 38 works
  7. 7 Jeanene Fogli United States · #3,516,940 worldwide 526 citations · 20 works
  8. 8 Paula J. Alvarez United States · #3,956,384 worldwide 382 citations · 31 works
  9. 9 Steven D. Woods United States · #5,094,724 worldwide 361 citations · 27 works
All ranked researchers at Vifor Pharma (United States)

What are the most cited papers from Vifor Pharma (United States)?

The most cited paper from Vifor Pharma (United States) is "Association of Serum Potassium with All-Cause Mortality in Patients with and without Heart Failure, Chronic Kidney Disease, and/or Diabetes" (Allan J. Collins, Bertram Pitt, Nancy L. Reaven et al., 2017), with 411 citations. Next come "Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial" (375) and "Poly(ortho esters): synthesis, characterization, properties and uses" (370).

Most cited papers
#PaperReleasedCitations
1 Association of Serum Potassium with All-Cause Mortality in Patients with and without Heart Failure, Chronic Kidney Disease, and/or Diabetes Allan J. Collins, Bertram Pitt, Nancy L. Reaven et al. · American Journal of Nephrology Open access 2017 411
2 Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial Rajiv Agarwal, Patrick Rossignol, Alain Romero et al. · The Lancet Open access 15 Sep 2019 375
3 Poly(ortho esters): synthesis, characterization, properties and uses Jorge Heller, John Barr, Steven Y Ng et al. · Advanced Drug Delivery Reviews Review Oct 2002 370
4 Microneedle-Based Vaccines Mark R. Prausnitz, John A. Mikszta, Michel Cormier et al. · Current topics in microbiology and immunology Book chapterOpen access 2009 314
5 Molecularly engineered poly(ortho ester) microspheres for enhanced delivery of DNA vaccines Chun Wang, Qing Ge, David Tsai Ting et al. · Nature Materials 15 Feb 2004 263
All 60 most cited papers, with filters and sorting

Which keywords describe research at Vifor Pharma (United States)?

By fractional works in 2022-now, weighted toward what it does more of than the world: Inflammation, Cancer Therapy, Chronic Kidney Disease, Heart Failure, Oxidative Stress, Immunotherapy, Cardiovascular Disease and Anemia.

▲ more of its work than of the world's◆ about the world's share▼ less than the world's

Size is fractional works in 2022-now in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Inflammation5▲ 3.5×20 topics
  2. Epidemiology4▲ 1.52×22 topics
  3. Oxidative Stress4▲ 3.4×13 topics
  4. Cancer Therapy3▲ 8.7×14 topics
  5. Chronic Kidney Disease3▲ 20×5 topics
  6. Heart Failure3▲ 11×4 topics
  7. Cardiovascular Disease3▲ 3.9×10 topics
  8. Immunotherapy3▲ 5.7×10 topics
  9. Quality of Life2▲ 2.3×6 topics
  10. Anemia2▲ 33×2 topics
  11. Iron Deficiency2▲ 61×2 topics
  12. Clinical Trials2▲ 4.4×8 topics
  13. Hyperkalemia2▲ 176×1 topic
  14. Neuroprotection2▲ 7.6×3 topics
  15. Prognostic Factors2▲ 6.1×7 topics
  16. Renin-Angiotensin-Aldosterone System Inhibitors2▲ 176×1 topic
  17. Drug Delivery2▲ 4.6×4 topics
  18. Immune Response2▲ 4.4×8 topics
  19. Neurological Disorders2▲ 4.5×5 topics
  20. Cell Death2▲ 9.8×5 topics
  21. Rituximab2▲ 16×3 topics
  22. Tumor Targeting2▲ 13×3 topics
  23. Nutrition2▲ 5.2×5 topics
  24. Cancer Treatment1▲ 8.9×5 topics
  25. Lymphoma1▲ 13×2 topics
  26. Transcriptional Regulation1▲ 12×5 topics
  27. Cancer Immunotherapy1▲ 12×3 topics
  28. Economic Evaluation1▲ 16×2 topics
  29. Hepcidin1▲ 51×1 topic
  30. Iron Regulation1▲ 51×1 topic
  31. Neurodegeneration1▲ 6.6×5 topics
  32. Tumor Regression1▲ 18×2 topics
  33. Cost-effectiveness Analysis1▲ 24×1 topic
  34. Drug Development Costs1▲ 71×1 topic
  35. Generic Drugs1▲ 71×1 topic
  36. Health Utility Measures1▲ 24×1 topic
  37. Immune Dysregulation1▲ 23×2 topics
  38. Filaggrin1▲ 34×1 topic
  39. Mutation1▲ 9.2×3 topics
  40. Skin Microbiome1▲ 34×1 topic

Which research topics does Vifor Pharma (United States) publish most on?

By volume in 2022-now: Potassium and Related Disorders, Iron Metabolism and Disorders, Health Systems, Economic Evaluations, Quality of Life and Pharmaceutical Economics and Policy.

  1. 1 Potassium and Related Disorders Pulmonary and Respiratory Medicine 2 works
  2. 2 Iron Metabolism and Disorders Hematology 1 works
  3. 3 Health Systems, Economic Evaluations, Quality of Life Economics and Econometrics 1 works
  4. 4 Pharmaceutical Economics and Policy Economics and Econometrics 1 works
  5. 5 Dermatology and Skin Diseases Dermatology 1 works
  6. 6 Amyotrophic Lateral Sclerosis Research Neurology 1 works
  7. 7 Protein Degradation and Inhibitors Molecular Biology 1 works
  8. 8 CAR-T cell therapy research Oncology 1 works
  9. 9 COVID-19 diagnosis using AI Radiology, Nuclear Medicine and Imaging 1 works
  10. 10 Innovation and Socioeconomic Development Business and International Management 1 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available44.6%not open55.4%

World: 40% of research is openly available.

with international co-authors39.1%domestic only60.9%

World: 18% is written across borders.

How has Vifor Pharma (United States)'s research output changed?

Output in 2022-2025 was 74% higher than in 2018-2021.

still counting200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Vifor Pharma (United States) as a percentage of every work published that year, 0.00029% in 2024.

still counting0.00025%0.00050%0.00075%Vifor Pharma (United States)0.00039% in 202519801990200020102020

Fractional works of Vifor Pharma (United States) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Somerset

All research institutions in Somerset

Share Vifor Pharma (United States)'s ranking

Vifor Pharma (United States) on Science Explorer

A card with Vifor Pharma (United States)'s standing and the fields it leads in, for a post or a slide. A link to this page previews as the same card.

Download the card

1200 × 630 PNG, sized for social posts, drawn from the latest snapshot.

Badges for a website1Each links back here and updates with every snapshot

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Vifor Pharma (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.